Intelligencia

Executive Summary

Intelligencia AI, founded in 2018 and based in London, offers an AI-powered platform that de-risks drug development by predicting the Probability of Technical and Regulatory Success (PTRS) for drug candidates. The company leverages curated clinical data and explainable AI algorithms to enable pharmaceutical and biotech companies to optimize portfolio strategy, clinical trial design, and licensing decisions. With a focus on oncology and other therapeutic areas, Intelligencia addresses a critical pain point in drug development: the high failure rate of clinical trials. By providing data-driven insights early in the pipeline, the platform helps clients allocate resources more efficiently, reduce costs, and increase the likelihood of successful approvals. As the industry increasingly adopts AI to accelerate R&D, Intelligencia is well-positioned to capture market share, particularly given its emphasis on transparency and explainability—key requirements for regulatory and internal decision-makers. Despite a competitive landscape that includes players like BenchSci, Insilico Medicine, and Recursion Pharmaceuticals, Intelligencia differentiates itself through its focus on regulatory success prediction and its curated dataset. The company has not disclosed funding rounds or revenue, suggesting it may still be in early growth stages. We assign a conviction score of 60, reflecting cautious optimism given the validated need for such tools but tempered by the crowded market and lack of publicly disclosed milestones. Key upcoming catalysts include a potential Series A or B funding raise (expected within 12 months), a strategic partnership with a top-20 pharma company (high impact, moderate probability), and expansion of their platform into additional therapeutic areas (e.g., rare diseases). These events could significantly enhance visibility, credibility, and commercial traction.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round70% success
• Q2 2027Strategic Partnership with Top-20 Pharma50% success
• Q3 2027Platform Expansion into New Therapeutic Areas60% success